These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29843133)

  • 1. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
    Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
    Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
    Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
    Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
    Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
    Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
    Gillissen B; Richter A; Richter A; Preissner R; Schulze-Osthoff K; Essmann F; Daniel PT
    J Biol Chem; 2017 Apr; 292(16):6478-6492. PubMed ID: 28154184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
    Deng Y; Wang Z; Zhang F; Qiao M; Yan Z; Wei Q; Wang J; Liu H; Fan J; Zou Y; Liao J; Hu X; Chen L; Yu X; Haydon RC; Luu HH; Qi H; He TC; Zhang J
    Cell Physiol Biochem; 2016; 39(3):871-88. PubMed ID: 27497986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
    Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
    Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
    Kim C; Lee JH; Baek SH; Ko JH; Nam D; Ahn KS
    Phytother Res; 2017 Jul; 31(7):1078-1089. PubMed ID: 28544385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
    Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
    J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
    Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
    Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
    Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
    Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
    Fishman MN; Tomshine J; Fulp WJ; Foreman PK
    PLoS One; 2015; 10(4):e0120877. PubMed ID: 25830512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
    Tei H; Miyake H; Fujisawa M
    Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.
    Fang Z; Jung KH; Yan HH; Kim SJ; Rumman M; Park JH; Han B; Lee JE; Kang YW; Lim JH; Hong SS
    Cell Physiol Biochem; 2018; 47(5):1751-1768. PubMed ID: 29953970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
    Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
    BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.